Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation

Xospata® is the first and the only FDA-approved FLT3-inhibiting therapy. Image courtesy of Astellas Pharma.



  • Xospata
  • Xospata
  • Xospata
  • Xospata
Close
Close
Close

Go Top